Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
6MW3211 in Relapsed or Refractory Lymphoma
NCT05446688Phase 2Unknown
- Sponsor
- Mabwell
- Start
- Sep 2022
- Primary completion
- Mar 2024
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of 6MW3211 in lymphoma, sponsored by Mabwell. Primary endpoint: Objective Response Rate at 1 year. Status: unknown.
02
Drugs
6MW3211
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT05446688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05446688.